1217481-36-1
Chemical Structure
Fumonisin B2-13C34
- CAS No.: 1217481-36-1
- Formula:13C34H59NO14
- Molecular Weight:739.58
IUPAC Name: (2R,2'R)-2,2'-((((5R,6R,7S,9S,16R,18S,19S)-19-amino-16,18-dihydroxy-5,9-di(methyl-13C)icosane-6,7-diyl-1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20-13C20)bis(oxy))bis(2-oxoethane-2,1-diyl-1,2-13C2))disuccinic-13C4 acid
InChIKey: UXDPXZQHTDAXOZ-BMUNAYDHSA-N
SMILES: O[13C]([13CH2][13C@@H]([13C](O)=O)[13CH2][13C](O[13C@@H]([13CH2][13C@@H]([13CH3])[13CH2][13CH2][13CH2][13CH2][13CH2][13CH2][13C@@H](O)[13CH2][13C@H](O)[13C@@H](N)[13CH3])[13C@@H]([13C@H]([13CH3])[13CH2][13CH2][13CH2][13CH3])O[13C]([13CH2][13C@H]([13C](O)=O)[13CH2][13C](O)=O)=O)=O)=O
Biological Activity: Fumonisin B2-13C34 is the 13C labeled Fumonisin B2 (HY-N6723)[1]. Fumonisin B2, a mycotoxin produced by Fusarium moniliforme in various grains, is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis[2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Fumonisin B2-13C34 | Fumonisin B2-13C34 is the 13C labeled Fumonisin B2 (HY-N6723). Fumonisin B2, a mycotoxin produced by Fusarium moniliforme in various grains, is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fumonisin B2 | 99.99% | Fumonisin B2 is a selective ceramide synthase inhibitor and carcinogenic mycotoxin with toxicity comparable to that of Fumonisin B1 (HY-N6719). Fumonisin B2 inhibits de novo sphingolipid biosynthesis by blocking the amide bond formation between fatty acids and dihydrosphingosine, which leads to a massive intracellular accumulation of free dihydrosphingosine, altered sphingosine levels, subsequent inhibition of cell proliferation, and induction of cell death. Fumonisin B2 is used to investigate the pathogenesis of diseases associated with Fusarium verticillioides contamination, including equine leukoencephalomalacia, porcine pulmonary edema syndrome, human esophageal cancer, and rat hepatocellular carcinoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-220. [Content Brief]
- [2]. Henry MH, et al. The toxicity of fumonisin B1, B2, and B3, individually and in combination, in chicken embryos. Poult Sci. 2001 Apr;80(4):401-7. [Content Brief]
- [3]. Wei T, et al. Natural occurrence of fumonisins B1 and B2 in corn in four provinces of China. Food Addit Contam Part B Surveill. 2013;6(4):270-4. [Content Brief]
Keywords
